In the BioHarmony Drug Report Database

"Preview" Icon

Lanadelumab

Takhzyro (lanadelumab) is an antibody pharmaceutical. Lanadelumab was first approved as Takhzyro on 2018-08-23. It has been approved in Europe to treat hereditary angioedemas. The pharmaceutical is active against plasma kallikrein.

 

Trade Name

 

Takhzyro
 

Common Name

 

lanadelumab
 

ChEMBL ID

 

CHEMBL3545189
 

Indication

 

hereditary angioedemas
 

Drug Class

 

Monoclonal antibodies: fully human, immunomodulating

Image (chem structure or protein)

Lanadelumab structure rendering